- 作者：Wai-Kay Seto ; Kevin Liu ; Danny Ka-Ho Wong ; James Fung ; Fung-Yu Huang ; Ivan Fan-Ngai Hung ; Ching-Lung Lai ; Man-Fung Yuen
- 关键词：TDF ; tenofovir disoproxil fumarate ; HBV ; hepatitis B virus ; CHB ; chronic hepatitis B ; HBsAg ; hepatitis B surface antigen ; HBeAg ; hepatitis B e antigen ; anti-HBs ; antibody to the hepatitis B surface antigen ; ALT ; alanine aminotransferase
- 刊名：Journal of Hepatology
- 出版年：2013
- 出版时间：October, 2013
- 年：2013
- 卷：59
- 期：4
- 页码：709-716
- 全文大小：878 K
Background & Aims
Patterns of serum hepatitis B surface antigen (HBsAg) decline during nucleos(t)ide analogue (NA) therapy have not been well investigated.Methods
We determined the cumulative serologic, virologic, and biochemical outcomes of 142 Asian CHB patients, with at least 6 months exposure to other NAs, receiving tenofovir with or without lamivudine for up to 3 years. Liver biochemistry, serum HBV DNA, and HBsAg levels were determined at baseline, 6 months and yearly from years 1 to 3.
Results
142, 123 (86.6 % ), and 70 (49.3 % ) CHB patients were followed up for 1, 2, and 3 years, respectively. Two phases of HBsAg decline were observed. Patients with baseline HBsAg ?3 log IU/ml, when compared to patients with baseline HBsAg <3 log IU/ml, had a greater median rate of HBsAg reduction through 3 years of treatment (0.155 and 0.039 log IU/ml/year respectively, p <0.001). Among patients with 3 years of follow-up, there was a significantly greater median rate of HBsAg reduction during the first year when compared to the second and third years (0.220, 0.136, and 0.081 log IU/ml/year respectively, p <0.001). HBeAg status, HBV genotype, and concomitant lamivudine therapy were not important determinants of HBsAg kinetics (all p >0.05). The 3-year cumulative virologic suppression rate was 93.3 % , with no cases of resistance detected.
Conclusions
Serum HBsAg levels in NA-experienced patients receiving tenofovir demonstrated a variable pattern of decline, with slower rates of reduction noted in patients with lower baseline HBsAg levels, and could explain the rarity of HBsAg seroclearance during NA therapy.